# LG Life Sciences

Organization · id `cardio:org-lg-life-sciences` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=LG+Life+Sciences>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 9 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: LG Life Sciences
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d (`cardio:ct-nct01787396`)
- Sponsors: Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia (`cardio:ct-nct01918332`)
- Sponsors: Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients (`cardio:ct-nct01928628`)
- Sponsors: Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin (`cardio:ct-nct01990469`)
- Sponsors: Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes (`cardio:ct-nct02089126`)
- Sponsors: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) (`cardio:ct-nct02126358`)
- Sponsors: Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (`cardio:ct-nct02770664`)
- Sponsors: Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study) (`cardio:ct-nct02831361`)
- Sponsors: Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. (`cardio:ct-nct03015909`)

## Provenance

Content hash: 59934722836ce5391cde28dbe8db798d0705b96e1fc8abc0d86bd3dfb21ad9f8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
